Resumen
Objectives: Since, to date, there are few epidemiological data assessing the diversity in the characteristics of breakthrough pain episodes, the present study was performed to assess the intra-individual variability in the episodes of breakthrough pain in patients with underlying chronic pain controlled with opioids. Methods: An observational, prospective and multicenter study (CADI study) was conducted in the context of the routine clinical practice of Spanish pain specialists recruiting opioid-treated patients with underlying chronic pain. Data were recorded in three visits (baseline, at 7 and 28 days post-inclusion) and by the patient on a patient´s diary card, specifically designed to characterise the first 8 breakthrough pain episodes (type, intensity –using 100 mm Visual Analog Scale- and duration of pain), to assess the intra-individual and inter-individual variability in the intensity, duration and typology of episodes of breakthrough pain. Results: 50 opioid-treated patients were recruited (23 with oncologic pain and 27 with non oncologic pain, mean age of 61.1 years, 62% females). For all three parameters, inter-patient variability was higher than intra-patient variability throughout the episodes. Nevertheless, we found intra-patient variability in maximum pain intensity, pain intensity at the end of the episode, pain relief and duration of the episode. Conclusions: This is the first study to quantify the intra-patient variability of breakthrough pain. The results show a great variability in terms of intensity and duration of the episode and its typology. Although inter-patient variability is higher, the intra-patient variability is important enough to be taken into account in optimizing the approach and treatment selection.Referencias
1. Brennan F, Carr DB, et al. Pain management: a fundamental human right. Anesth Analg 2007; 105: 205-221.
2. Fishman SM. Recognizing pain management as a human right: a first step. Anesth Analg 2007; 105: 8-9.
3. Anwari JS. Pain management: citizenship or human right? Anesth Analg 2008; 106: 678.
4. Yates JW, Kirch R. Regulatory barriers for adequate pain control. Asian Pac J Canver Prev 2010; 11: 17-21.
5. Ospina MB, Taenzer P, Rashiq S, et al. A systematic review of the effectiveness of knowledge translation interventions for chronic noncancer painmanagement. Pain Res Manag 2013; 18: e129-41.
6. Ehrich EW, Bolognese JA, Watson DJ, et al. Effect of rofecoxib on measures of health-related quality of life in patients with osteoarthritis. Am J Manag Care 2001; 7: 609-616.
7. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333.
8. Ogboli-Nwasor E, Makama J, Yusufu L. Evaluation of knowledge of cancer pain management among medical practitioners in a low-resource setting. J Pain Res 2013; 6: 71-77.
9. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat Med 2001; 15: 243-246.
10. Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic non cancer pain. J Pain 2006; 7: 583-591.
11. Davies AN, Vriens J, Kennett A, et al. An observational study of oncology patients' utilization of breakthrough pain medication. J Pain Symptom Manage 2008; 35: 406-411.
12. Smith H. A comprehensive review of rapid-onset opioids for breakthrough pain. CNS Drugs 2012; 26: 509-535.
13. Fine PG, Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage 1998; 16: 179-183.
14. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81: 129-134.
15. Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 2013; 46: 619-628.
16. Davies A, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 2011; 15: 756-763.
17. Friendlander AH, Ettinger RL. Karnofsky performance status scale. Spec Care Dentist 2009; 29: 147-148.
18. Huskisson EC, Jones J, Scott PJ. Application of visual-analogue scales to the measurement of functional capacity. Rheumatol Rehabil 1976; 15: 185-187.
19. Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 2007; 96: 1828-1833.
20. Mercadante S. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. Expert Opin Pharmacother 2012; 13: 873-878.
21. Egan TD, Sharma A, Ashburn MA, et al. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology 2000; 92: 665-673.
22. Porta-Sales J, Garzón C, Julià J, et al. Dolor irruptivo en cáncer. Med Clin (Barc) 2010; 135: 280-285.
23. Fornasari D. Pain mechanisms in patients with chronic pain. Clin Drug Investig 2012; 32: 45-52.
24. Ablin JN, Buskila D. Personalized treatment of pain. Curr Rheumatol Rep 2013; 15: 298-303.
